Prostate Cancer Urine Test
An experimental urine test has reportedly been identified “at least as good” as the prostate-specific antigen (PSA) test for predicting aggressive prostate cancer in men according to new study published in a British Journal Nature on February 12 2009.
The urine test assesses levels of prostate cancer specific metabolites which could eventually be added to PSA and other tools for monitoring prostate cancer progression according to the researchers.
Metabolites were studied in the investigation from samples of tissue, blood, or urine associated with benign prostate tissue, early-stage prostate cancer, and metastatic prostate cancer.
Investigations showed elevated concentration levels of the amino acid sarcosine, appearing to be the strongest indicator of advanced disease. Levels of sarcosine were elevated in 79% of the metastatic prostate cancer samples and in 42% of the locally advanced cancer samples. Sarcosine was not found in the cancer free samples.
The investigation however, had a small study sample, and requires further validation and development of the scientific approach of analysing metabolites as prostate cancer biomarkers.
For more on this research: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression
An experimental urine test has reportedly been identified “at least as good” as the prostate-specific antigen (PSA) test for predicting aggressive prostate cancer in men according to new study published in a British Journal Nature on February 12 2009.
The urine test assesses levels of prostate cancer specific metabolites which could eventually be added to PSA and other tools for monitoring prostate cancer progression according to the researchers.
Metabolites were studied in the investigation from samples of tissue, blood, or urine associated with benign prostate tissue, early-stage prostate cancer, and metastatic prostate cancer.
Investigations showed elevated concentration levels of the amino acid sarcosine, appearing to be the strongest indicator of advanced disease. Levels of sarcosine were elevated in 79% of the metastatic prostate cancer samples and in 42% of the locally advanced cancer samples. Sarcosine was not found in the cancer free samples.
The investigation however, had a small study sample, and requires further validation and development of the scientific approach of analysing metabolites as prostate cancer biomarkers.
For more on this research: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression
No comments:
Post a Comment